{
    "clinical_study": {
        "@rank": "77395", 
        "arm_group": [
            {
                "arm_group_label": "LongGnRH agonist protocol(controlgroup)", 
                "arm_group_type": "Active Comparator", 
                "description": "Long GnRH agonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol   valerate"
            }, 
            {
                "arm_group_label": "Long protocol-leuprolide acetate", 
                "arm_group_type": "Experimental", 
                "description": "Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer"
            }, 
            {
                "arm_group_label": "GnRHantagonist protocol(control group)", 
                "arm_group_type": "Active Comparator", 
                "description": "GnRH antagonist protocol ( control group) Luteal Phase Support:  Vaginal progesterone + 4mg oral estradiol   valerate"
            }, 
            {
                "arm_group_label": "antagonist protocol-leuprolide acetate", 
                "arm_group_type": "Experimental", 
                "description": "GnRH antagonist protocol Luteal Phase Support:  Vaginal progesterone + 4mg oral estradiol   valerate +  subcutaneous 0.5mg leuprolide   acetate     fifth and tenth day after     embryo transfer"
            }
        ], 
        "brief_summary": {
            "textblock": "This prospective clinical trial evaluates the effect of a two dose GnRH agonist administered\n      in the luteal phase on the outcome of ART cycles stimulated with the long GnRH agonist and\n      GnRH antagonist protocol."
        }, 
        "brief_title": "The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "detailed_description": {
            "textblock": "This prospective clinical trial evaluates the effect of a two dose GnRH agonist administered\n      in the luteal phase on the outcome of ART cycles stimulated with the long GnRH agonist and\n      GnRH antagonist protocol. Decision between each of these two protocols was subjective and\n      depended on the clinical context.In addition to routine luteal phase support with\n      progesterone and estradiol valerate,women  received two dose of GnRH agonist  on the fifth\n      and tenth day after ET.Live birth  rate was the primary outcome measure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Couples undergoing ART with their own gametes.\n\n          -  Couples having at least one good embryo available for transfer.\n\n          -  Normoresponder\n\n          -  Infertility etiology is unexplained\n\n          -  ovulation triggered by intramuscular injection of 10000 IU of HCG\n\n        Exclusion Criteria:\n\n        Patients older than 38 years old\n\n          -  High and poor responder patients"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "38 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02114645", 
            "org_study_id": "ZTB-5030", 
            "secondary_id": "ZTB5030"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Long protocol-leuprolide acetate", 
                    "antagonist protocol-leuprolide acetate"
                ], 
                "description": "in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate  is given subcutaneously as luteal phase support", 
                "intervention_name": "Leuprolide acetate", 
                "intervention_type": "Drug", 
                "other_name": "lucrin"
            }, 
            {
                "arm_group_label": [
                    "LongGnRH agonist protocol(controlgroup)", 
                    "Long protocol-leuprolide acetate", 
                    "GnRHantagonist protocol(control group)", 
                    "antagonist protocol-leuprolide acetate"
                ], 
                "description": "crinone gel is applied  till fetal heart beat is detected", 
                "intervention_name": "vaginal progesterone", 
                "intervention_type": "Drug", 
                "other_name": "crinone gel"
            }, 
            {
                "arm_group_label": [
                    "LongGnRH agonist protocol(controlgroup)", 
                    "Long protocol-leuprolide acetate", 
                    "GnRHantagonist protocol(control group)", 
                    "antagonist protocol-leuprolide acetate"
                ], 
                "description": "estrofem is given twice a day", 
                "intervention_name": "4 mg oral estradiol valerate", 
                "intervention_type": "Drug", 
                "other_name": "estrofem 2mg tablet"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Progesterone", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate", 
                "Leuprolide", 
                "Deslorelin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Luteal phase support,GnRH agonist,ART cycles", 
        "lastchanged_date": "April 13, 2014", 
        "link": {
            "description": "Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.", 
            "url": "http://www.ncbi.nlm.nih.gov/pubmed/?term=16926261"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Ankara", 
                    "country": "Turkey", 
                    "state": "Cankaya", 
                    "zip": "06500"
                }, 
                "name": "Zekai Tahir Burak Hospital"
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "4", 
        "official_title": "To Evaluate the Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes in Both GnRH Agonist and GnRH Antagonist Treated Ovarian Stimulation Protocols", 
        "overall_contact": {
            "email": "nagihancengaver@gmail.com", 
            "last_name": "Nagihan Cengaver, MD", 
            "phone": "+905556309298"
        }, 
        "overall_official": {
            "affiliation": "Zekai Tahir Burak Maternity and Teaching Hospital", 
            "last_name": "Nagihan Cengaver, Resident", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Live Birth Rate", 
            "safety_issue": "No", 
            "time_frame": "42 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02114645"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zekai Tahir Burak Maternity and Teaching Hospital", 
            "investigator_full_name": "Nagihan CENGAVER", 
            "investigator_title": "Resident", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Ongoing pregnancy", 
                "safety_issue": "No", 
                "time_frame": "more than 20 weeks"
            }, 
            {
                "measure": "miscarriage", 
                "safety_issue": "No", 
                "time_frame": "up to 20 weeks"
            }, 
            {
                "measure": "OHSS", 
                "safety_issue": "No", 
                "time_frame": "up to 10 weeks"
            }
        ], 
        "source": "Zekai Tahir Burak Maternity and Teaching Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zekai Tahir Burak Maternity and Teaching Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}